Validation of the Mercy TAPE

计划入组 642 人 · 首次发布于 2012 年 1 月 10 日

A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo

计划入组 100 人 · 首次发布于 2015 年 12 月 31 日

Phase I Human Analytics (HALO) Study

计划入组 2,000 人 · 首次发布于 2022 年 6 月 21 日

RNAi Therapeutics(Halo-Bio RNAi Therapeutics, Inc.)

CITI-002

Valo D102

Halo Pharmaceutical, Inc.

United States

Blue Halo Biomedical, LLC

United States

Halo Pharmaceutical Canada, Inc.

Canada

Mercy BioAnalytics Raises $59 Million Series B to Commercialize Breakthrough Ovarian Cancer Screening Technology

Blood-Based Test Shows Superior Early Lung Cancer Detection Compared to Standard CT Screening

Waters Acquires Halo Labs to Enhance Biologic Therapy Analysis Capabilities